



PRESS RELEASE

For Immediate Release

Contact: info@globalcancertechnology.com

GLOBAL CANCER TECHNOLOGY SHOWS PROMISING PRE-CLINICAL DATA WITH GCT-007 AND CHECKPOINT INHIBITOR TREATING TAMOXIFEN-RESISTANT BREAST CANCER

Dr. Traci Lyons and her team at the University of Colorado show that GCT-007 in combination with checkpoint inhibitor therapy delays tumor progression and confirmed that GCT-007 restores sensitivity to tamoxifen treatment in an immunocompetent animal model of tamoxifen

San Diego, CA, May 16, 2024, 2024 – Global Cancer Technology, Inc. announced today that Dr. Traci Lyons, and doctoral candidate Rachel Steinmetz at the University of Colorado, Anschutz Campus, have demonstrated that combination therapy using GCT-007 and immune checkpoint therapy significantly delays breast cancer progression and growth in an immune-competent animal model of endocrine-resistant breast cancer. Dr. Lyons also confirmed her previous data showing that treatment with GCT-007 can restore sensitivity to tamoxifen treatment in tamoxifen-resistant tumors.

“We are delighted to see the positive effects of GCT007 in combination with immune checkpoint inhibitor therapy in this pre-clinical animal study of treatment-resistant breast cancer and look forward to continuing our productive and exciting collaboration with Dr. Lyons,” said Dr. M. Karen Newell Rogers, chief scientific consultant for GCT.

“We are impressed with the combination effects of GCT-007 with immune therapy and the impressive pre-clinical results we are seeing in our animal model of estrogen receptor-positive (ER+) breast cancer”. said Dr. Lyons.

John Clark, the CEO of Global Cancer Technology, stated, “Global Cancer Technology is proud that GCT-007 augments the tremendous efforts that Dr. Traci Lyons and her lab are making in her fight against deadly breast cancers.”

Global Cancer Technology is a non-revenue biopharma company raising investment capital to enter a Phase 1 clinical trial for glioblastoma.
Globalcancertechnology.com

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.